JZJ Chain Drugstore Corporation. Class A

JZJ Chain Drugstore Corporation. Class A

SSSE:605266
13.13
CNY
-0.16
(-1.20%)
-1.42EPS
2.48BMarket Cap
Apr 29Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
16.04
17.52
19.56
22.36
26.38
33.68
38.85
39.53
49.69
58.94
60.13
60.22
58.23
Basic EPS, GAAP
0.17
0.17
0.68
0.9
1.27
1.6
2.18
2.27
2.47
2.69
0.83
1
-1.42
Free Cash Flow per Basic Share
0.03
-1.22
- -
0.49
0.85
1.95
1.6
2.71
2.71
4.7
1.56
6.92
- -
Dividend per Share
0.2
0.07
0.05
0.05
0.32
0.41
0.04
0.94
1.03
1.33
1.57
1.64
1.78
Book Value per Share
1.5
1.78
2.44
3.36
4.38
5.64
12.29
13.54
16.71
18.5
17.86
17.3
14.4
Tangible Book Value per Share
1.34
1.62
2.27
3.17
4.13
4.81
11.64
10.28
1.63
2.37
1.6
1.03
-1.83
Basic Weighted Avg Shares
104
105
105
105
105
105
115
132
151
154
154
148
149
Sales/Revenue/Turnover
1,667
1,844
2,054
2,347
2,766
3,529
4,466
5,235
7,514
9,081
9,283
8,921
8,651
Operating Margin (%)
2.53
2.25
4.97
6.15
7.13
6.95
7.08
7.85
7.8
7.4
3.93
4.77
0.91
Depreciation Expense
11
10
- -
16
16
23
25
482
610
749
829
811
- -
Net Income, GAAP
17
18
71
95
134
168
251
301
374
414
128
148
-211
Effective Tax Rate (%)
41.02
40.11
21.97
27.67
26.34
23.88
17
16.46
15.04
20.7
24.26
28.5
- -
Profit Margin (%)
1.04
0.97
3.45
4.04
4.83
4.76
5.62
5.74
4.98
4.56
1.38
1.66
-2.44
Working Capital
-57
-130
-64
-29
17
30
579
76
-286
-923
-785
-1,047
-1,749
LT Debt
2
1
- -
47
41
36
645
868
2,155
1,950
2,099
1,477
1,075
Total Equity
150
179
246
341
448
578
1,702
1,893
2,568
2,845
2,781
2,672
2,224
Return on Invested Capital (%)
- -
5.16
20.99
20.86
23.09
25.71
13.98
9.84
8.58
6.78
1.94
2.12
- -
Return on Capital (%)
- -
6.91
25.76
24.1
26.66
29.44
15.18
11.61
10.58
8.48
3.38
3.33
- -
Return on Common Equity (%)
- -
10.47
32.05
31.18
32.95
32
21.76
16.57
16.66
15.22
4.53
5.42
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,910
2,821
3,228
LT Borrowings
779
815
643
LT Finance Leases
511
473
432
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
155
155
155
Market Capitalization
2,942
2,263
2,479

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,060
3,982
4,318
Cash, Cash Equivalents & STI
693
871
884
Accounts Receivable, Net
991
734
1,001
Inventories
2,097
2,075
2,142
Total Current Liabilities
5,180
5,212
6,066
Payables & Accruals
- -
- -
- -
ST Debt
2,910
2,821
3,228
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.27%
10.3%
-3.92%
Free Cash Flow
- -
89.02%
325.36%
Net Income, GAAP
44.58%
0.3%
15.63%
Sales/Revenue/Turnover
17.75%
15.98%
-3.9%
Total Cash Common Dividend
323.73%
549.15%
0.43%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,314
2,171
2,250
2,548
9,283
2025
2,294
2,162
- -
2,372
8,921
2026
2,091
2,092
2,096
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.34
0.07
0.25
0.18
0.83
2025
0.22
0.26
- -
0.32
1
2026
0.24
0.12
-2.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
1.2
0.14
0.15
1.57
2025
0.1
1.27
- -
0.13
1.64
2026
0.12
1.4
0.14
- -
- -

Company Description

CEO
Bo Lan
Full Time Employees
16,536
Sector
Retail trade
Industry
Drugstore chains
Address
No. 10, Qiying Street Kunming YU China 650224
IPO Date
Dec 1, 2020
Website
jzj.cn
Business
Jianzhijia Pharmaceutical Chain Group Co., Ltd. operates a comprehensive retail network across China, focusing on pharmaceutical and convenience services. The company manages a substantial number of directly operated stores, augmented by its online sales platforms. Its offerings encompass prescription and over-the-counter medicines, health and nutritional products, a variety of medical devices, and daily essential goods for personal care and household use. Established in 1998, with its headquarters situated in Kunming, China, the group has significantly expanded its footprint, now managing over 4,700 retail locations nationwide as of September 2023, through a blend of organic growth and strategic acquisitions.